Literature DB >> 30763184

Further Progress for Patients with Breast Cancer.

Daniel F Hayes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30763184     DOI： 10.1056/NEJMe1816059

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Real-World Breast Cancer Patient Follow-Up Practices by Medical Oncologists in India-A Survey Report.

Authors:  Amol Patel; Vineet Govinda Gupta; Bhupesh Guleria; Chandan K Das; Prashant Mehta; Kaushik Mahadevapura Ramegowda
Journal:  South Asian J Cancer       Date:  2022-02-05

2.  Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1).

Authors:  Kimberly S Corbin; William G Breen; Jonathan B Strauss
Journal:  Clin Transl Radiat Oncol       Date:  2020-07-03

3.  Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.

Authors:  Yongqi Zhen; Rongyan Zhao; Minjuan Wang; Xing Jiang; Feng Gao; Leilei Fu; Lan Zhang; Xian-Li Zhou
Journal:  Theranostics       Date:  2020-07-02       Impact factor: 11.556

4.  Overexpression of LncRNA BM466146 Predicts Better Prognosis of Breast Cancer.

Authors:  Yunxiang Zhang; Xiaotong Dong; Yang Wang; Liquan Wang; Guiyan Han; Lvcheng Jin; Yanping Fan; Guodong Xu; Dawei Yuan; Jie Zheng; Xiangyu Guo; Peng Gao
Journal:  Front Oncol       Date:  2021-01-29       Impact factor: 6.244

Review 5.  Triple-negative breast cancer: new treatment strategies in the era of precision medicine.

Authors:  Song-Yang Wu; Hai Wang; Zhi-Ming Shao; Yi-Zhou Jiang
Journal:  Sci China Life Sci       Date:  2020-08-11       Impact factor: 6.038

6.  Circular RNA hsa_circRNA_002178 silencing retards breast cancer progression via microRNA-328-3p-mediated inhibition of COL1A1.

Authors:  Ting Liu; Ping Ye; Yuanyuan Ye; Sen Lu; Baosan Han
Journal:  J Cell Mol Med       Date:  2020-01-19       Impact factor: 5.310
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.